Anti-IL17A in Axial Spondyloarthritis—Where Are We At?

Knowledge regarding the mechanisms of the IL17–IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroid...

Descripción completa

Detalles Bibliográficos
Autor principal: Cheung, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241317/
https://www.ncbi.nlm.nih.gov/pubmed/28149838
http://dx.doi.org/10.3389/fmed.2017.00001
_version_ 1782496162541993984
author Cheung, Peter P.
author_facet Cheung, Peter P.
author_sort Cheung, Peter P.
collection PubMed
description Knowledge regarding the mechanisms of the IL17–IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis. Clinical studies and current issues surrounding the use of secukinumab will be discussed.
format Online
Article
Text
id pubmed-5241317
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-52413172017-02-01 Anti-IL17A in Axial Spondyloarthritis—Where Are We At? Cheung, Peter P. Front Med (Lausanne) Medicine Knowledge regarding the mechanisms of the IL17–IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis. Clinical studies and current issues surrounding the use of secukinumab will be discussed. Frontiers Media S.A. 2017-01-18 /pmc/articles/PMC5241317/ /pubmed/28149838 http://dx.doi.org/10.3389/fmed.2017.00001 Text en Copyright © 2017 Cheung. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Cheung, Peter P.
Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
title Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
title_full Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
title_fullStr Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
title_full_unstemmed Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
title_short Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
title_sort anti-il17a in axial spondyloarthritis—where are we at?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241317/
https://www.ncbi.nlm.nih.gov/pubmed/28149838
http://dx.doi.org/10.3389/fmed.2017.00001
work_keys_str_mv AT cheungpeterp antiil17ainaxialspondyloarthritiswhereareweat

Ejemplares similares